Targets › TOP2B
4 programs from 4 companies in 4 trials: 2 Phase 2, 1 Phase 3, 1 Phase 4; Oncology; next expected readout Oct 2027.
Key decatenating enzyme that alters DNA topology by binding to two double-stranded DNA molecules, generating a double-stranded break in one of the strands, passing the intact strand through the broken strand, and religating the broken strand. Plays a role in B-cell differentiation. (UniProt, Q02880)
Open in Phaseline: the race on TOP2B, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Hospital JP Garrahan | ESHAP Combination chemotherapy: Etoposide (topoisomerase II inhibitor), Methylprednisolone (cort | TOP2B, NR3C1 | Phase 4 | Pediatric Hodgkin's Disease | Oct 2027 |
| Stichting Hemato-Oncologie voor Volwassenen Nederland | Dexrazoxane DNA topoisomerase II inhibitor | TOP2A, TOP2B | Phase 3 | DLBCL - Diffuse Large B Cell Lymphoma | Dec 2028 |
| M.D. Anderson Cancer Center | Dexrazoxane Hydrochloride DNA topoisomerase II inhibitor | TOP2A, TOP2B | Phase 2 | Acute Myeloid Leukemia | Dec 2027 |
| CNS Pharmaceuticals | Berubicin DNA topoisomerase II inhibitor | TOP2A, TOP2B | Phase 2 | Glioblastoma Multiforme, Adult | – |
Glioblastoma Multiforme, Adult (1) Acute Myeloid Leukemia (1) DLBCL - Diffuse Large B Cell Lymphoma (1) Pediatric Hodgkin's Disease (1)
small molecule (2), mixed (2)
CNS Pharmaceuticals (1) M.D. Anderson Cancer Center (1) Stichting Hemato-Oncologie voor Volwassenen Nederland (1) Hospital JP Garrahan (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.